We recently showed that macrophage-stimulating protein (MSP), a serum protein homologous to hepatocyte growth factor, promotes ciliary motility by activating its receptor, RON, on the airway ciliated epithelium. To investigate the functional involvement of MSP and RON in bronchiectasis, in which mucociliary clearance (MCC) is impaired, ®rst we examined RON expression on the bronchial ciliated epithelium of patients with bronchiectasis. We con®rmed RON expression at the apical surface of bronchial ciliated epithelium of patients with bronchiectasis as well as those of normal human bronchus. Next, we examined whether MSP is present in sputum of patients with bronchiectasis and normal control subjects. By Western blotting, we found that half of the MSP in sputum is present as a biologically active a/b chain heterodimer (mature MSP). In addition, we found that the MSP concentrations in sputum were signi®cantly elevated in patients with bronchiectasis (n=8; 16?8+3?0 ng ml 71 ) compared with normal controls (n=9; 8?4+2?4 ng ml 71 ; P50?05). In contrast, the dierence in concentrations of serum MSP (pro-MSP) was not signi®cant between the two groups. These results indicate that (i) MSP is supplied to the airways and converted to a biologically active form, (ii) MSP is increased in patients with bronchiectasis compared with normal controls. Taken together, our ®ndings suggest that increased MSP may be involved in compensation for impaired MCC in bronchiectasis.
Introduction
Bronchiectasis is a disease of mucus hypersecretion and recurrent airway in¯ammation that causes destruction of the ciliated epithelium and submucosa with elastic and muscular tissue degeneration (1, 2) . It has been demonstrated that mucociliary clearance (MCC) is impaired in the airways of patients with bronchiectasis (3, 4) . Impaired MCC may be due to abnormal mucociliary function, abnormal load and rheology of mucus, or abnormal interaction between cilia and mucus (5) . The lungs of patients with bronchiectasis are frequently colonized by Haemophilus in¯uenzae and Pseudomonas aeruginosa (6) . Soluble products Pseudomonas aeruginosa, such as pyocyanin and 1-hydroxyphenazine, were found to inhibit ciliary beat frequency (CBF) of human respiratory cilia in vitro and cause the reduction of tracheal mucus velocity in vivo (7, 8) . Thus, ciliary dysfunction may be involved in the impairment of MCC in patients with bronchiectasis.
Recently, we have demonstrated that the receptor tyrosine kinase RON is expressed on the airway ciliated epithelium, and that its ligand macrophage-stimulating protein (MSP) promotes ciliary motility in these cells by activating RON (9) . These ®ndings suggest that MSP functions as one regulatory factor of ciliary motility and plays an important role in the airway mucociliary transport. To date, however, the biological signi®cance of MSP in the airway mucociliary transport in vivo has not been clari®ed.
MSP is an 80-kD serum protein that was originally found to stimulate murine resident peritoneal macrophages to make a chemotactic response to C5a (10) . MSP belongs to a family characterized by the presence of a highly conserved triple disulphide loop structure (kringle domain). The family includes prothrombin, plasminogen, urokinase and hepatocyte growth factor, the latter of which shows high homology to MSP (45% identity at the amino acid level) (11±14). Proteins in this family are secreted as single-chain precursors that acquire biological activity upon cleavage by speci®c serine proteases. It has been shown that MSP is synthesized by hepatocytes (11, 13, 15) and secreted as biologically inactive pro-MSP, the single-chain precursor of MSP, into the circulation. In addition, pro-MSP is reported to be cleaved to a disulphide-linked a/b heterodimer (mature MSP) by serine proteases such as enzymes of the intrinsic coagulation cascade (16) .
To explore the role of MSP and RON in bronchiectasis, initially we investigated whether RON is expressed on the bronchial ciliated epithelium of patients with bronchiectasis. In addition, we investigated whether MSP is present in induced sputum and measured the concentrations of MSP in induced sputum of patients with bronchiectasis and normal control subjects. In this paper, we show that RON is expressed at the apical surface bronchial ciliated epithelium of patients with bronchiectasis. Furthermore, we show that half of the MSP in sputum is present as biologically active mature MSP, and that MSP concentrations in sputum are signi®cantly increased in patients with bronchiectasis compared with normal controls.
Methods

SUBJECTS
Seventeen subjects participated in the study after giving informed consent. Eight were patients with bronchiectasis. Nine were control subjects who had no history of pulmonary diseases. The chest roentgenograms and pulmonary function tests of nine controls were normal. The study was approved by the Institutional Review Board of Kumamoto University. Patients with bronchiectasis were diagnosed by chest roentgenogram and computed tomography. All cases of bronchiectasis occurred with postinfectious causes and recurrent persistent infections. None of them had immunoglobulin de®ciency or Kartagener's syndrome. All subjects underwent clinical, hematological, and chemical examinations in order to exclude acute infectious exacerbations. Forced vital capacity (FVC) and forced expiratory volume in 1 sec (FEV 1 ) were measured by a dry rollingseal spirometer (Chestac-65V, Chest Co., Tokyo, Japan). The clinical characteristics of these subjects are shown in Table 1 .
SPUTUM INDUCTION AND PROCESSING
Before collection of samples subjects were asked to rinse their mouth, swallow water, and blow their nose to minimize contamination with saliva and post-nasal drip. Then inhalation of hypertonic saline (3%) was performed using an ultrasonic nebulizer (NE-U11, Omron Co., Tokyo, Japan). Inhalation of hypertonic saline was continued for 15±20 min until the sputum volume was over 1 ml. The nebulizer generated particles with a mass diamter of 1±5 mm and had an output of 1?5 ml min 71 . Subjects were encouraged to cough throughout the procedure, and they regularly interrupted inhalation of hypertonic saline in order to expectorate sputum into a clean plastic dish.
The assessment of the quality of the obtained samples was performed as described by Pin et al. (17) . One thousand microlitres of sputum was immediately cooled on ice and combined with 950 ml of phosphate buered saline (PBS) and 50 ml of 2 mM p-amidinophenyl methanesulphonyl¯u oride hydrochloride (APMSF) (Wako Pure Chemical, Osaka, Japan). The samples were then homogenized and centrifuged at 14 000 rpm at 48C for 20 min. The obtained supernatants were frozen immediately at 7708C.
IMMUNOHISTOCHEMISTRY
Subsegmental bronchi (diameter: 3±6 mm) of normal control and patients with bronchiectasis were obtained from surgical and autopsy samples. Immediately after the tissues were obtained, they were mounted in OCT 4583 embedding compound (Miles Inc, Elkhart, IN, U.S.A.) and then frozen in liquid nitrogen. Serial cryostat sections (6-mm thick) cut in a MICROM cryomicrotome were air dried, and ®xed in acetone for 10 min at 48C. After washing with PBS three times, cryostat sections were treated with 5 mM orthoperiodic acid solution for 10 min to block endogenous peroxidase activity as described (18) . The sections were stained with a rabbit polyclonal antibody against RON (0?2±0?5 mg ml 71 ) (Santa Cruz Biotechnology, Inc., CA, U.S.A.) by the indirect immunoperoxidase method using horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Amersham International, Little Chalfont, U.K.). Peroxidase activity was visualized using 3,3'-diaminobenzidine (Dojindo, Kumamoto, Japan) as a substrate. To con®rm the speci®c reactivity of anti-RON with the RON protein, one of the serial sections was incubated with a mixture of anti-RON antibody and an excess molar ratio of antigen peptide (Santa Cruz Biotechnology, Inc.), then processed as described above.
IMMUNOPRECIPITATION AND WESTERN BLOTTING
Each 300 ml sample of induced sputum obtained from bronchiectasis subjects and from control subjects was incubated for 6 h at 48C with protein G-Sepharose (Pharmacia, Uppsala, Sweden) precoated with a mouse monoclonal anti-human MSP antibody (MSP89-2S, American Type Culture Collection HB-10522, Rockville, MD) with an equal volume of 26Triton lysis buer [100 mM Hepes, pH 7?4, 2% Triton X-100, 300 mM NaCl, 2 mM EDTA and protease inhibitors (50 mg ml 71 aprotinin, 1 mM PMSF, 100 mM leupeptin, 25 mM pepstatin A)]. Immune complexes were collected on protein G-Sepharose. Immunoprecipitates were boiled for 3 min at 1008C in sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buer with 5% 2-mercaptoethanol (2-ME), then resolved by SDS-PAGE using 10% polyacrylamide as described by Laemmli (19) . Recombinant human pro-MSP and MSP (Toyobo Co., Shiga, Japan) were also applied to the gel for reference markers. After electrophoresis, proteins were transferred onto a PVDF membrane (Nihon Millipore Ltd, Yonezawa, Japan). The a-chain of mature MSP and pro-MSP were evaluated with a rabbit polyclonal anti-human MSP antibody (Toyobo Co.). Speci®c binding was detected using the enhanced chemiluminescence (ECL) detection system (Amersham International).
QUANTIFICATION OF MSP IN SERUM AND INDUCED SPUTUM
MSP concentrations in serum and the supernatant of induced sputum were measured by sandwich-type ELISA. This ELISA system detects both MSP and pro-MSP. Brie¯y, a microtitre plate was coated overnight at 48C with a mouse monoclonal anti-human MSP antibody. After blocking with 3% bovine serum albumin in PBS, the plate was incubated with diluted standards or samples. After washing, the plate was incubated with a rabbit polyclonal anti-human MSP antibody, followed by HRP-conjugated anti-rabbit IgG (Amersham International). Speci®c binding was detected by incubating the plate with 0?05 M phosphate-citrate buer containing 0?4 mg ml 71 o-phenylenediamine dihydrochloride and 0?4 mg ml 71 urea hydrogen peroxide (Sigma Chemical Co., ST. Louis, MO, U.S.A.). The absorbance at 450 nm was measured in an automated microplate reader (Molecular Devices Corp., Sunnyvale, CA, U.S.A.). MSP concentrations were determined by interpolation of thier absorbance from a standard curve.
STATISTICAL ANALYSIS
Results are shown as mean +SEM. The dierences between groups were compared with Mann±Whitney's U-tests. A value of P50?05 was considered signi®cant.
Results
We studied eight patients with bronchiectasis and nine control subjects. There was no signi®cant dierence in FVC (%pred) and FEV 1 /FVC (%) between the two groups. Haemophilus in¯uenzae was detected in two patients and Pseudomonas aeruginosa was detected in another two patients ( Table 1) .
To examine the expression of RON on the bronchial ciliated epithelium, we performed immunohistochemical staining of bronchial tissues obtained from normal control and two patients with bronchiectasis using an anti-RON antibody. The bronchial ciliated epithelium was clearly stained with anti-RON in both normal control [ Fig. 1(A) ] and two patients with bronchiectasis [ Fig. 1(C,E) ]. Notably, the positive staining was localized at the apical surface of the cells. In addition, the positive staining was also observed in damaged ciliated epithelium as well as relatively intact ciliated epithelium. The speci®c reactivity of anti-RON antibody with RON was con®rmed by the ®nding that positive staining was completely blocked by an excess molar ratio of antigen peptide [ Fig. 1(B,D,F) ]. Negative staining of goblet cells in bronchial epithelium was con®rmed by comparing immunohistochemical staining with anti-RON and PAS staining using serial sections (data not shown).
To test our prediction that MSP is present in sputum of patients with bronchiectasis and normal control subjects, we performed immunoprecipitations using induced sputum samples from three bronchiectasis subjects and three control subjects with a monoclonal anti-human MSP antibody. Western blotting with a rabbit polyclonal antihuman MSP antibody that detects mature MSP and pro-MSP showed that these sputa contain comparable levels of MSP a-chain and pro-MSP (Fig. 2) . These results indicate that half of the MSP in sputum is present as biologically active mature MSP in both patients with bronchiectasis and normal controls. 
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Next, to investigate the role of MSP in bronchiectasis, we measured concentrations of MSP in serum and induced sputum of patients with bronchiectasis and normal control subjects. As shown in Table 2 , serum MSP (pro-MSP) levels were 7?8+0?5 mg ml 71 in patients with bronchiectasis and 8?1+0?3 mg ml 71 in normal controls. There was no signi®cant dierence between the two groups. On the other hand, MSP levels in induced sputum were 16?8+3?0 ng ml 71 in patients with bronchiectasis and 8?4+2?4 ng ml 71 in normal controls (P50?05). Thus, MSP levels were signi®cantly increased in sputum but not in the serum of patients with bronchiectasis as compared with normal controls.
Discussion
It has been recognized that the eectiveness of MCC depends on three factors: ciliary function, secretion of mucins and other macromolecules, and¯uid secretion. In particular, ciliary function and interaction between cilia and mucus have been shown to be critical for airway mucociliary transport (5) . In our recent study, we showed that the MSP-RON signalling pathway functions as one regulatory system of ciliary motility in vitro (9); however, the signi®cance of this pathway in the airway mucociliary transport in vivo remains to be elucidated.
In this study, we con®rmed that RON is also expressed at the apical surface of bronchial ciliated epithelium of patients with bronchiectasis as well as those of normal human bronchus. In addition, we con®rmed that MSP is present in the sputum of patients with bronchiectasis and normal control subjects, and that half of the MSP in sputum is present as a biologically active a/b chain heterodimer (mature MSP). Previous studies have shown that MSP is produced by hepatocytes (11, 13, 15) and secreted into the circulation as biologically inactive pro-MSP, the single-chain precursor of MSP, and maintained in serum as pro-MSP (20) . Furthermore, pro-MSP has been shown to be cleaved to a biologically active a/b chain heterodimer by serum kallikrein and coagulation Factors XIIa and XIa in vitro (16) . Our results suggest that MSP is supplied to the airways from the circulation and converted to an active form. Taken together with the ®nding that the MSP receptor, RON, is localized to the apical surface of airway ciliated epithelium, it seems reasonable to conclude that MSP in sputum binds to and activates RON on the airway ciliated epithelium resulting in stimulation of ciliary motility in vivo.
Wang et al. previously showed that resident murine peritoneal macrophages, one of the target cells for MSP, have enzymatic activities that proteolytically cleave pro-MSP (20) . These results suggest that control of MSP activity can occur at the level of the target cell by proteolytic cleavage of pro-MSP to mature MSP. Since the mechanism of proteolytic cleavage of serum pro-MSP to mature MSP in sputum remains to be clari®ed, it will be of interest to explore whether airway ciliated epithelial cells, one of the target cells for MSP, contain enzymatic activity that proteolytically cleaves pro-MSP to mature MSP.
The Haemophilus in¯uenzae and Pseudomonas aeruginosa frequently colonize in the respiratory tract of patients with bronchiectasis (6) , and these bacterial and in¯ammatory cell products have been shown to have a detrimental eect on the mucociliary transport apparatus. For example, soluble products of Haemophilus in¯uenzae and Pseudomonas aeruginosa can decrease CBF (21, 22) ; pyocyanin, 1hydroxyphenazine and rhamnolipids were found to be the putative agents in Pseudomonas aeruginosa (7, 23, 24) . Furthermore, the following in¯ammatory mediators released into the airway lumen during in¯ammation have been shown to decrease CBF: hydrogen peroxide (25), human neutrophil elastase (26) and neutral protease (27) . Thus, the eect of these bacterial products and in¯ammatory mediators in vivo is cilioinhibition, and this inhibition On the contrary, a number of mediators have been shown to increase CBF in vitro and in vivo (5), however, the involvement of these mediators in bronchiectasis is not fully examined. In the present study, the concentrations of MSP in sputum were signi®cantly elevated in patients with bronchiectasis compared with normal controls. On the other hand, the concentrations of serum MSP (pro-MSP) were similar in the two groups. These ®ndings indicate that biologically active mature MSP is signi®cantly increased in the airways but not in the serum of patients with bronchiectasis. The high concentrations of MSP in sputum of patients with bronchiectasis may be caused by the increase in transudation of serum pro-MSP during the in¯ammatory process. Thus, MSP may play a compensatory role in MCC of patients with bronchiectasis.
An increase in CBF usually translates into an increased MCC, yet MCC has been depressed in bronchiectasis. It is possible that, despite the stimulatory eect of MSP on ciliary motility, abnormal load and rheology of mucus predominantly contribute to the impairment of MCC in bronchiectasis (28) . Moreover, since ciliated epithelia of patients with bronchiectasis are damaged and accompanied by loss of epithelial ciliation due to ciliotoxic bacterial products and in¯ammatory mediators (26), those may not eectively respond to MSP. At present both the mechanism of MSP activation in vivo and control of its concentration in the airways are under investigation.
In conclusion, we have shown that MSP is present in sputum as biologically active mature MSP and signi®cantly increased in sputum of patients with bronchiectasis. In the MCC of patients with bronchiectasis, MSP might act as a ciliary activity factor to compensate for impaired MCC.
